Results and Discussion Results from testing 78 samples from 58 HIV-1 positive deferred plasma donors by 12 tests employing 10 different methods are illustrated.

Slides:



Advertisements
Similar presentations
Development of an oral fluid assay capable of differentiating recent from established HIV infection Niel Constantine 1, Ligia Peralta 1, Anne Sill 2, Kristen.
Advertisements

HIV-1/HIV-2 PLUS O To detect HIV Antibody Groups M & O Genetic Systems™ HIV-1/HIV-2 PLUS O EIA   HIV Subtypes and Variants   Description of HIV-1/HIV-2.
Performance of Bio-Rad Genetic Systems HIV-1/HIV-2 Plus O EIA Followed by Multispot or OraQuick Advance in a Dual Immunoassay HIV Testing Strategy Laura.
Using longitudinal, population-based HIV surveillance to measure the real-world impacts of ART scale-up in KwaZulu- Natal, South Africa Frank Tanser Presentation.
Comparing the New EIAs with Old Standbys: Florida Bureau of Laboratories Verification Data HIV Diagnostics: New Developments and Challenges Feb. 28, 2005.
Title: PEOPLE LIVING WITH HIV/AIDSIN EGYPT: ROLE OF COMMUNITY PHARMACIST Authors: Nahla Maher Hegab Pharmacy graduate. Institution: College of pharmacy,
Use of dried blood spots (DBS) or dried serum/plasma spots (DSS/DPS) to detect recent HIV-1 seroconversion by the BED-CEIA Bharat Parekh, PhD Centers for.
Newborn Screening Quality Assurance Program Newborn Screening Quality Assurance Program Comparison of Less Sensitive HIV Incidence Tests for the Serological.
12/6/07 v.3CDC 2007 HIV Diagnostic Conference1 Diagnosis of HIV-1 Infection in Phase I & II HIV Vaccine Trials RW Coombs 1, J Dragavon 1, B Metch 2, CJ.
Use of avidity reagent. Panbio Buffered Avidity Reagent Mild protein-denaturing solution that may be useful in differentiating recent infections from.
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
A Simple and Inexpensive Particle Agglutination Assay for Identifying Recent HIV Infection Niel Constantine 1, Li Hong 2, Kristen Kreisel 1, Anne Sill.
Primary HIV Infection: the CDC study Pragna Patel, MD MPH Medical Epidemiologist Behavioral and Clinical Surveillance Branch DHAP, CDC February 28, 2005.
Is Nucleic Acid Testing for Organ Donors the ‘Right’ Choice? Reference: Humara A, Morrisb M, Blumbergc R, et al. Nucleic acid testing (NAT) of organ donors:
Thoughts on Simplifying the Estimation of HIV Incidence John Hargrove, Alex Welte, Paul Mostert [and others]
Enhancing HIV/AIDS Surveillance in California California Department of Public Health Office of AIDS Guide for Health Care Providers.
Unit 5: Core Elements of HIV/AIDS Surveillance
Unit 4: Monitoring Data Quality For HIV Case Surveillance Systems #6-0-1.
Introduction to Molecular Epidemiology Jan Dorman, PhD University of Pittsburgh School of Nursing
NAT Yield from Real Time Testing of Organ Donors for HIV-1 RNA and HCV RNA Safer Organs and No False Positive Results Claudia Chinchilla-Reyes, MB(ASCP)1,
Guidelines for Laboratory Testing and Result Reporting for Antibody to Hepatitis C Virus Miriam J. Alter, Ph.D. Division of Viral Hepatitis Centers for.
Thoughts on Biomarker Discovery and Validation Karla Ballman, Ph.D. Division of Biostatistics October 29, 2007.
Chemometrics Method comparison
Tests for Recent Infection and CDC’s Plans for the Detuned IND Bernard M. Branson, M.D. Centers for Disease Control and Prevention.
Screening and Early Detection Epidemiological Basis for Disease Control – Fall 2001 Joel L. Weissfeld, M.D. M.P.H.
Jennifer Kates, Kaiser Family Foundation Eric Lief, Center for Strategic and International Studies/UNAIDS July 2006 International Assistance for HIV/AIDS.
E992750C 1 Replacement of HIV-1 p24 Antigen Screening with HIV-1 RNA Nucleic Acid Testing (NAT) for Whole Blood Donations S.L. Stramer, R.A. Porter, J.P.
Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics Divisions of HIV/AIDS Prevention National Center for HIV/AIDS, Viral Hepatitis,
CLINICAL TRIAL OF THE HEMA-STRIP HIV RAPID TEST USING FINGERSTICK BLOOD, WHOLE BLOOD, PLASMA, AND SERUM Niel T. Constantine 1, Dan Bigg 2, Daniel Cohen.
HIV, HCV, and HBV NAT Controls Formulation, Stability and Performance Mark Manak BBI Diagnostics, Inc. A Division of SeraCare Life Sciences, Inc. SoGAT.
Multiple Choice Questions for discussion
Unit 1: Overview of HIV/AIDS Case Reporting #6-0-1.
Epidemiology of Hepatitis C Infection in Canada Robert S. Remis MD, MPH, FRCPC Department of Public Health Sciences University of Toronto 1st Canadian.
21th VHPB meeting on “Prevention of viral hepatitis in Italy: lessons learnt and the way forward” Catania, 7-8 november 2002 RESIDUAL RISK OF TRANSFUSION-
Development of a detuned oral assay for recent HIV infection F. Priddy 1, P. Phelan 1, P. Tambe 1,2, C. del Rio 1 1 Emory University School of Medicine,
ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES XVIII International AIDS Conference, July , Vienna Austria Recent Trends in estimated HIV-1.
Decreasing Incidence of Pertussis in Massachusetts Following the Introduction of Tdap Noelle Cocoros, Nancy Harrington, Rosa Hernandez, Jennifer Myers,
Update on Assay Development George J. Dawson, Ph.D. Infectious Diseases: Core R & D Abbott Laboratories West Nile Virus.
Bias in estimates of HIV incidence based on the detuned assay: A proposed solution Robert S Remis, Robert WH Palmer, Janet M Raboud Department of Public.
Quality Control Lecture 5
E001372A 1 ARC Experience with Indeterminate Blood Donors Susan L. Stramer, Ph.D. National Confirmatory Testing Laboratory American Red Cross.
Xenotropic Murine Leukemia Virus-Related Retrovirus: CCR Assay Development.
LOWERING THE DETECTION LIMITS OF HIV-1 VIRAL LOAD USING REAL-TIME IMMUNO-PCR FOR HIV-1 P24 ANTIGEN Niel T. Constantine, Ph.D., Daniel Edelman, M.S., Janet.
Development of Standard Reagents for WNV NAT M. Rios, A. Grinev, K. Sirnivasan, O. Wood, S. Daniel, I. Hewlett CBER/FDA.
Evaluation of the Presage™ ST2 ELISA Jun Lu 1, David G. Grenache 1,2 1 ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT 2 Department.
The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and.
Organization of statistical research. The role of Biostatisticians Biostatisticians play essential roles in designing studies, analyzing data and.
A Universal Testing Programme for Blood Borne Viruses in an Urban Emergency Department – a call for widespread ED testing in Ireland S O’Connell 1, D Lillis.
10 May Understanding diagnostic tests Evan Sergeant AusVet Animal Health Services.
DISCONTINUATION OR NO DISCONTIUNATION: COMPARISON OF SINGLE UNIT HIV ANTIGEN TESTING VS. POOLED NAT TESTING Gerald Schochetman, Ph.D. Abbott Laboratories.
Postgraduate books recommended by Degree Management and Postgraduate Education Bureau, Ministry of Education Medical Statistics (the 2nd edition) 孙振球 主.
Laboratory Enhancement Study: Using the detuned assay to determine HIV incidence in Ontario October 1999 – July 2000 Robert S. Remis, Carol Major, Carol.
BIOSTATISTICS Lecture 2. The role of Biostatisticians Biostatisticians play essential roles in designing studies, analyzing data and creating methods.
 Routine viral diagnostics: indirect and direct detection of viruses. ◦ Indirect detection: serological tests; ◦ Direct detection:  Viral antigens;
Dengue fever caused by dengue virus (DENV), a member of Flaviviridae leads to large global disease burden. Detection of immunoglobulin M (IgM) and nucleic.
BioPlex 2200 HIV Ag-Ab Assay
Herpes Simplex Virus Type 2 infection among U.S. military service members: Public Health Implications and Opportunities for HIV Prevention Christian T.
Abbott Laboratories ConfidentialPage 1 Update on West Nile Virus George J. Dawson, Ph.D. Abbott Laboratories.
The HIV epidemic in Ontario: An epidemiologic update Robert S. Remis, MD, MPH, FRCPC, Department of Public Health Sciences, University of Toronto Presentation.
Central American Certificate Course: HIV Monitoring and Evaluation for HIV/AIDS Policy and Program Management BZ Unit 2 – Post test CR ES GT NI PA January.
Update on CBER HIV-1 Subtype panel
Aiying Chen, Scott Patterson, Fabrice Bailleux and Ehab Bassily
General Approach in Investigation of Hemostasis
NUCLEIC ACID AMPLIFICATION TESTING DETECTS HIV TRANSMISSION RISK IN SEROLOGICALLY- TESTED BLOOD DONOR UNITS. |Presented by Miss Shemau Muniru| Authors:
Public Health Surveillance
ImmunoWELL Zika Virus Serology.
Epidemiologic Update on the HIV Epidemic in Ontario
TRACE INITIATIVE: Overview
Introduction to epidemiology
Rose Nyirenda Ministry of Health, Malawi
Presentation transcript:

Results and Discussion Results from testing 78 samples from 58 HIV-1 positive deferred plasma donors by 12 tests employing 10 different methods are illustrated in Figure 1. Of 58 donors, 25 had consensus results (43%, 21 prevalent, 4 incident). Another 13 donors had consensus results on all but one test (22%, 7 prevalent, 6 incident). Twenty donors (34%) had one or more units in the ‘no consensus’ category. Consensus results (incident or prevalent by all tests) were obtained for 38/78 samples (49%, 33 prevalent, 5 incident). Another 17 samples had the same result for all but one test (22%, 8 prevalent, 9 incident). ‘No consensus’ was defined as more than one discrepant result, and 23 samples (29%) fell into this category. Seventeen same-donor series were collected over short periods of time (2-9 days, mean 4.3, median 3), so plasma units from the same donor might be expected to fall into the same category. This was true for 14/17 donors. In summary, 38 samples from 25 donors had consistent results by all test methods, and 55 samples from 38 donors had results consistent by all or all but one test method. No consensus was found for 23 samples from 20 donors. Where consensus was lacking, one cause may be varying definitions of recent vs. long-standing or incident vs. prevalent for different methods. Defined ‘recent’ intervals ranged from <120 days to <279 days for different methods, and for some methods the interval is still being determined. Accurate estimates of HIV incidence do not depend on a specific definition of recent vs. long-standing, but rather on accurate and reproducible discrimination between the two categories, whatever the cutoff. If continued experience demonstrates that different methods have different discrimination points, useful information may be available from both approaches. Performance Panel PRB601 was assembled from samples that had consensus results (7 incident, 8 prevalent) with at least 11 of 12 tests. Characteristics of the panel members and data from several incidence test methods are described in Tables 1 and 2. One HIV diagnostic test showed some discrimination between consensus incident and consensus prevalent samples. HIV antigen was positive for three consensus incident samples in PRB601, and negative for all consensus prevalent samples. HIV antibody tests and HIV RNA showed no discriminatory power at all, as expected. Abstract Background: Accurate laboratory assessment of incidence vs. prevalence or early vs. long-standing HIV infection is valuable for epidemiological studies and for diagnostic assessment of individuals. We have completed a study of samples from a large group of deferred plasma donors with unknown dates of HIV infection using several candidate HIV incidence test methods to categorize samples as ‘consensus incident’, ‘consensus prevalent’ or ‘lacking consensus’ by a variety of methods. Materials and Methods: Samples tested were from a repository of well- characterized plasma units from deferred donors who were confirmed HIV positive. HIV incidence test methods included less-sensitive, avidity index, and methods using novel approaches. The PRB601 panel was assembled by aliquoting samples from units that tested incident or prevalent by at least 11 of the 12 test methods used, and by preparing a data sheet with test results for HIV markers and for nine incidence test methods (four less- sensitive, two avidity index, and three other approaches). Results: Of 78 samples tested by 12 methods, 42% were prevalent or long-standing infection by all methods. Only 6% were incident or recent infections by all methods, but if one candidate method was not considered, 18% were consensus incident. There was a lack of consensus (more than one method in disagreement with others) in 29% of this sample set, some of which may be due to variations in the definition of recent. Eight consensus prevalent and seven consensus incident samples were assembled into a panel for evaluating incidence tests. Conclusions: A clear understanding of HIV incidence (the rate of new infections) is important for formulating health care policy and efforts to fight the epidemic. Although long seroconversion series (that would constitute a gold standard) do not currently exist, useful information can be derived from samples with unknown seroconversion dates if consensus results are found from multiple incidence test methods based on different principles. PRB601 is a commercially available panel of consensus incident and consensus prevalent samples. Methods HIV incidence methods described to date have all involved measuring differences in immune responses between recent and long-standing infections. The methods can be classified as below: Less Sensitive (LS): these tests involve ‘de-tuning’ a commercially available HIV method to make it less sensitive by diluting samples, so that samples from early infection (that are positive on the unmodified test) will be below a specified cutoff, while samples from long-standing infection will be above the cutoff. Results are expressed as Standard Optical Density (SOD) using a calibrator to normalize results. LS tests were the first incidence methods developed, and have been the most studied. 1,2 Avidity Index (AI): these tests exploit the lower avidity of early vs. ‘mature’ antibodies for the target HIV protein antigens. In AI methods, the sample is split: one aliquot is treated with a chaotropic agent in buffer and the other with buffer alone. Both aliquots are then tested using a commercially available anti-HIV test method, and ODs are compared using a ratio expressed as a percentage of treated to untreated sample. Early infection samples will have a lower ratio, as antibody- antigen complexes will have been disrupted by the chaotropic agent. 3,4 Novel epitopes: these tests detect antibody responses to HIV epitopes that have been empirically found to be expressed in early infection more intensely than in long-standing infection. In the HIV-RI method, results are expressed as mean OD and compared to a calibrator. 5 BED-CEIA: this test is an IgG-capture EIA where increasing proportion of gp41- IDR specific Abs are detected by BED-biotin peptide. Results are normalized using a calibrator OD and expressed as OD-n. 6 NRL HIV-1: this test identifies individuals infected with HIV-1 within 120+/-16 days by detecting a specific antigen-antibody interaction that is transient in recent infection. Results are quantified using a standard curve, and values >20 ug/ml are considered indicative of early infection. To identify HIV-1 infected individuals prior to day 30, this assay must be performed in parallel with a p24 antigen assay. 7 References 1.Janssen et al. JAMA 1998 Jul 1;280(1):42-8: Erratum: JAMA 1999 May 26;281(20): Kothe et al. JAIDS 2003 Aug 15;33(5): Suligoi et al. JCM 2002 Nov;40(11): Jenner et al. Poster presentation at 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 10-14, Barin et al. Poster presentation LB21 at The 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, July 13-16, Hu et al. AIDS Res and Hum Retro 2003;19: Wilson et al. AIDS 2004;18: Conclusions  A study of 78 samples from 58 donors with unknown HIV seroconversion dates has demonstrated that the Less Sensitive, Avidity Index, HIV-RI, BED CEIA, and NRL approaches to incidence testing produce results that are consistent with one another in the majority of cases.  Further analysis of the data taking into account differing definitions of recent infection may resolve some of the ‘no consensus’ samples.  BBI Diagnostics has produced a Performance Panel (PRB601) for the evaluation of newly developed or implemented incidence test methods.  PRB601 has 15 members, including 7 consensus incident and 8 consensus prevalent samples, and is supplied with a data sheet containing results from nine incidence test methods performed in five internationally recognized referee laboratories. Introduction  Tests for incidence vs. prevalence of HIV infection are needed by epidemiologists, public health professionals and researchers.  Policymakers use the information generated to answer questions like “Are current efforts to slow the HIV epidemic effective?”  Distributions of funds depend on the answers to these questions.  To date, no test for HIV incidence vs. prevalence has won wide acceptance, but a number of candidate methods have been developed.  To evaluate these methods, series of samples collected from individuals recently infected through the first year following infection would constitute ‘gold standards’, but such series are extremely rare.  BBI organized an international study of samples from a large group of U.S. deferred plasma donors with unknown dates of HIV infection using several HIV incidence test methods to categorize samples as ‘consensus incident’, ‘consensus prevalent’, or ‘lacking consensus’.  From this study, BBI Diagnostics, a division of SeraCare Life Sciences, Inc. developed a Performance Panel with consensus incident and consensus prevalent samples and a data set to assist developers and evaluators of tests for recent HIV infection. Materials BBI supplied to nine laboratories a set of 78 samples from plasma units representing single bleeds or short series (2-3 bleeds) from 58 HIV-1 positive deferred plasma donors with unknown seroconversion dates. Eight laboratories supplied test results for twelve incidence test methods in time for preparation of this poster. One laboratory did not receive three samples, and one laboratory was not able to test five samples for one of the two methods it reported. Plasma samples from fifteen units that tested either ‘incident’ (recent infection) or ‘prevalent’ (long-standing infection) by at least 11/12 methods were developed into a commercially available HIV-1 Incidence/Prevalence Performance Panel (BBI Panel PRB601). Acknowledgements The authors are most grateful to Dr. Yiping Zhang for advice and assembly of the poster, and to collaborators and data donors Joanne Mei, Michele Owens, Bharat Parekh, Thomas Folks and Ron Otten of the U.S. Centers for Disease Control and Prevention (CDC). METHOD COMPARISON OF HIV TESTS FOR RECENT INFECTION PE Garrett 1, S Crush-Stanton 2, V MacKeen 2, J Thurston 2, B Weiblen 2, MP Busch 3, B Werner 4, J Jenner 4, F Barin 5, KM Wilson 6, EM Dax 6 1 SeraCare Life Sciences, Inc., W. Bridgewater, MA; 2 BBI Diagnostics, W. Bridgewater, MA; 3 Blood Centers of the Pacific, San Francisco, CA; 4 MA State Laboratory Institute, Boston, MA; 5 Université F Rabelais, Tours, France; 6 National Serology Reference Laboratory, Melbourne, Australia Figure 1. Of 58 HIV-1 positive deferred plasma donors, 28 (48%) were classified as prevalent by all or all but one method, and 10 (17%) were classified as incident by all or all but one method. No consensus was found for 20 deferred donors (34%). Table 1. HIV Diagnostic Tests Table 2. HIV Incidence Tests Table 2. HIV incidence test results on final panel members sorted by incident or prevalent categories. Table 1. Characterization of panel members with HIV diagnostic tests. A preliminary panel configuration presented at CVS 2004 has been modified. The data here and in Table 2 were collected on the final panel members APHL Infectious Disease Conference Orlando, FL March 2-4, HIV Diagnostics Conference Orlando, FL February 28-March 1, 2005